UDENYCA® (pegfilgrastim-cbqv)
Neutropenia in patients receiving myelosuppressive chemotherapy
ApprovedCommercial
Key Facts
Indication
Neutropenia in patients receiving myelosuppressive chemotherapy
Phase
Approved
Status
Commercial
Company
About Coherus BioSciences
Coherus BioSciences leverages its expertise in biologics development and commercialization to bring biosimilar and novel cancer therapies to market. The company has successfully launched UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar to Humira®, establishing a commercial foundation. Its strategic focus has expanded to include a promising immuno-oncology pipeline, most notably the clinical-stage anti-TIGIT antibody, toripalimab, acquired from Junshi Biosciences, positioning Coherus for future growth in the competitive oncology landscape.
View full company profile